Insider · CIK 0001214504
Ronald Pepin
officer
Files at CLDX (Celldex Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 29, 2026 |
| Dec 15, 2025 | CLDX Celldex Therapeutics, Inc. | MOption exercise Common Stock | +8,333 | $9.02 | $75k | 9,097 | Dec 17, 2025 |
| Dec 15, 2025 | CLDX Celldex Therapeutics, Inc. | MOption exercise Common Stock | +11,000 | $2.78 | $31k | 20,097 | Dec 17, 2025 |
| Dec 15, 2025 | CLDX Celldex Therapeutics, Inc. | MOption exercise Incentive Stock Option (right to buy)derivative | -8,333 | $0.00 | $0 | 5,000 | Dec 17, 2025 |
| Dec 15, 2025 | CLDX Celldex Therapeutics, Inc. | MOption exercise Incentive Stock Option (right to buy)derivative | -11,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 9, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.